DOJ Telemedicine Fraud Case Underscores Compliance Risks for Health Care Organizations
Key Takeaways
- A US Department of Justice (DOJ) enforcement action against a telemedicine company owner highlights continued scrutiny of arrangements involving telemedicine prescribing, kickbacks, and medically unnecessary orders billed to Medicare.
- The case illustrates how regulators are pursuing all participants in alleged fraud schemes, including practitioners, telemedicine companies, marketing firms, pharmacies, and durable medical equipment suppliers.
- For health care organizations, the enforcement action highlights the importance of robust compliance controls governing prescribing practices, financial relationships, and documentation supporting medical necessity.
A recent DOJ enforcement action against the owner of 2 telemedicine companies highlights the government's continued focus on fraud schemes involving telemedicine, medically unnecessary prescribing, and improper financial relationships tied to federal health care programs.
On June 30, 2026, the DOJ announced that a Georgia nurse practitioner and telemedicine company owner was sentenced to 120 months in prison and ordered to pay more than $66 million in restitution after pleading guilty to conspiracy to commit wire fraud and health care fraud. According to the DOJ, the scheme resulted in more than $136 million in fraudulent Medicare claims involving durable medical equipment (DME) and prescription drugs.
Although the case centers on criminal conduct, it also offers important compliance lessons for telemedicine providers, pharmacies, DME suppliers, and health care organizations participating in federally funded programs.
Telemedicine Remains an Enforcement Priority
According to the DOJ, the defendant owned and operated 2 telemedicine companies that allegedly obtained orders for orthotic braces and prescription drugs that were not medically necessary.
Federal prosecutors alleged that illegal kickbacks were paid to medical providers in exchange for signing orders and prescriptions for Medicare beneficiaries, and that many of the prescriptions were signed without a legitimate clinical need. The prescriptions and DME orders were then sold to marketing companies, which allegedly transferred them to pharmacies and brace suppliers that submitted reimbursement claims to Medicare.
The case reflects continuing federal scrutiny of telemedicine arrangements that rely on high-volume prescribing without individualized clinical decision-making.
Although telemedicine has become an established component of health care delivery, regulators continue to distinguish legitimate virtual care from business models that use remote encounters primarily to generate reimbursable orders or prescriptions.
Anti-Kickback Risks Extend Throughout the Supply Chain
One of the central allegations in the case involved payments made in exchange for physician and practitioner orders.
According to the DOJ, the telemedicine companies allegedly paid illegal kickbacks to medical providers to sign orders for orthotic braces and prescription drugs, while receiving compensation when those orders were sold to downstream marketing companies.
The allegations illustrate how Anti-Kickback Statute (AKS) exposure can extend beyond direct payments between providers and manufacturers.
Organizations throughout the health care supply chain—including telemedicine platforms, marketing companies, pharmacies, and DME suppliers—may face liability when financial arrangements influence medical decision-making or generate referrals for items reimbursable by federal health care programs.
Medical Necessity Remains a Core Compliance Requirement
The enforcement action also underscores the importance of documenting medical necessity.
According to the DOJ, beneficiaries allegedly received braces and prescription medications that were not clinically indicated, with some individuals receiving orders for multiple orthotic devices despite no demonstrated need. Prosecutors alleged that practitioners working with the telemedicine companies signed orders for 4 or more orthotics for thousands of beneficiaries, while dozens reportedly received orders for 10 or more devices.
Medical necessity remains one of the foundational requirements for Medicare reimbursement. Even where documentation appears complete, claims may be subject to enforcement if the underlying services or products were not supported by appropriate clinical evaluation.
For organizations participating in Medicare and other federal health care programs, maintaining documentation that demonstrates individualized patient assessment and clinical justification remains essential.
Third-Party Marketing Relationships Continue to Draw Scrutiny
The DOJ's allegations also highlight ongoing regulatory concerns surrounding third-party marketing arrangements.
According to prosecutors, the telemedicine companies sold signed prescriptions and DME orders to marketing companies, which then transferred them to pharmacies and brace suppliers that sought Medicare reimbursement.
Federal enforcement agencies have repeatedly cautioned that marketing organizations can create significant compliance risks when compensation is tied to the generation of prescriptions, referrals, or reimbursable orders.
Health care organizations should conduct appropriate due diligence before entering relationships with lead generators, marketing firms, or telehealth vendors whose compensation structures could implicate fraud and abuse laws.
Compliance Implications for Providers and Pharmacies
Although the criminal case focused on the conduct of specific individuals, it reinforces several broader compliance principles applicable across the health care industry.
Organizations should evaluate whether their compliance programs adequately address the following:
- Clinical independence in prescribing decisions
- Documentation supporting medical necessity
- Financial relationships with marketers, referral sources, and contractors
- Oversight of telemedicine workflows
- Monitoring of high-volume prescribing or ordering patterns
- Internal auditing of Medicare claims and supporting documentation
Compliance programs should also ensure that practitioners retain independent medical judgment and that compensation arrangements do not create incentives inconsistent with federal fraud and abuse laws.
Broader Enforcement Trends
The case aligns with the DOJ's continued emphasis on combating health care fraud involving telemedicine, prescription drugs, and DME.
In recent years, federal enforcement actions have increasingly targeted complex networks involving multiple participants—including practitioners, telemedicine companies, pharmacies, marketers, laboratories, and medical equipment suppliers—rather than focusing solely on individual providers.
For compliance professionals, the enforcement action serves as a reminder that regulators continue to scrutinize both the clinical integrity of prescribing decisions and the financial relationships supporting reimbursement under federal health care programs.
As telemedicine continues to evolve, organizations participating in virtual care models should expect sustained oversight of prescribing practices, referral arrangements, and claims submitted to Medicare and other government payers.
References
- Telemedicine Company Owner and Author of Health Care Compliance Books Sentenced for $136M Medicare Fraud Scheme. US Department of Justice. Press release. Published June 30, 2026. Accessed July 1, 2026. https://www.justice.gov/opa/pr/telemedicine-company-owner-and-author-health-care-compliance-books-sentenced-136m-medicare
- US Department of Justice. Health Care Fraud Unit. Criminal Division. https://www.justice.gov/criminal-fraud/health-care-fraud-unit
